Mirxes (HKG:2629) unit Mirxes International entered into an agreement with Xeraya Opportunities Fund PCC to form a joint venture named MYRNA DIAGNOSTICS, a Monday Hong Kong bourse filing said.

The two parties will contribute $2 million and $3 million to the JV firm and hold a 40% and 60% stake, respectively, according to the micro ribonucleic acid technology company.

The JV company will engage in the R&D, commercialization, and obtaining of regulatory approval for cancer early detection and other nucleic acid-based tests in Malaysia.